Our Experts Pioneered DNA-Encoded Library (DEL)-Driven Drug Discovery

Our Experts Advance Small Molecule Discovery
Since 2009, X-Chem has led the way in DNA-encoded library (DEL) science and continues to evolve drug discovery. By combining DEL data with medicinal chemistry and computational sciences, we transform data into insights that accelerate and improve small molecule discovery. We partner with pharma and biotech innovators to deliver the clarity and confidence needed to move programs forward.

History of X-Chem from DEL Innovation to Chemomics

Unmatched Technology, Scientific Talent, and Trusted Partnerships Make X-Chem the Industry Standard

2009

Founded by a team of DEL inventors and experts.

2009

First DEL patent application filed covering X-Chem’s technology methods.

July 2010

Entered first drug discovery partnership.

May 2012

Completed the first electrophilic DEL and performed the first covalent selection.

September 2013

Licensed three drug discovery programs, validating services strategy with global pharma.

February 2014

Created the world’s first screening library to exceed 100 billion compounds.

April 2017

Published discovery of novel modulators to GPCR.

December 2019

Licensed 75th discovery program.

June 2020

Synthesized 100th DEL.

August 2020

Published results of collaboration with Google, using DEL data to drive machine learning.

January 2021

X-Chem acquired IntelliSyn, establishing screen-to-lead service capabilities.

October 2021

Acquired Comlnnex, extending functional and global leadership by adding a premier European discovery services provider.

October 2021

Acquired Glamorous AI, further enabling our DEL-powered AI solutions.

September 2025

Introduced chemomics, integrating DEL scale data with computational sciences and medicinal chemistry to deliver new insights and accelerate the path from discovery to development.